HIF-1α Protein

Pathway Diagram

flowchart TD
    HIF1A["HIF1A"]
    style HIF1A fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    Microglial_Metabolic_Reprogram["Microglial Metabolic Reprogramming"]
    HIF1A -->|"associated with"| Microglial_Metabolic_Reprogram
    AEROBIC_GLYCOLYSIS["AEROBIC GLYCOLYSIS"]
    HIF1A -->|"activates"| AEROBIC_GLYCOLYSIS
    Bladder_Tumorigenesis["Bladder Tumorigenesis"]
    HIF1A -->|"involved in"| Bladder_Tumorigenesis
    Cancer_Stemness["Cancer Stemness"]
    HIF1A -->|"associated with"| Cancer_Stemness
    VEGF["VEGF"]
    HIF1A -->|"regulates"| VEGF
    BNIP3["BNIP3"]
    HIF1A -->|"activates"| BNIP3
    AGGF1["AGGF1"]
    HIF1A -->|"upregulates"| AGGF1
    Cancer["Cancer"]
    HIF1A -->|"therapeutic target"| Cancer
    IDH2["IDH2"]
    IDH2 -->|"associated with"| HIF1A
    BMAL1["BMAL1"]
    BMAL1 -->|"regulates"| HIF1A
    EGLN2["EGLN2"]
    EGLN2 -->|"inhibits"| HIF1A
    NLRP3_inhibition["NLRP3 inhibition"]
    NLRP3_inhibition -->|"contributes to"| HIF1A
    FOXO3["FOXO3"]
    FOXO3 -->|"interacts with"| HIF1A
    APOPTOSIS["APOPTOSIS"]
    APOPTOSIS -->|"activates"| HIF1A
    TNF["TNF"]
    TNF -->|"associated with"| HIF1A
    style Microglial_Metabolic_Reprogram fill:#006494,stroke:#888,color:#e0e0e0
    style AEROBIC_GLYCOLYSIS fill:#006494,stroke:#888,color:#e0e0e0
    style Bladder_Tumorigenesis fill:#006494,stroke:#888,color:#e0e0e0
    style Cancer_Stemness fill:#ef5350,stroke:#ff8a65,color:#e0e0e0
    style VEGF fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style BNIP3 fill:#4a1a6b,stroke:#ce93d8,color:#e0e0e0
    style AGGF1 fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style Cancer fill:#ef5350,stroke:#ef5350,color:#e0e0e0
    style IDH2 fill:#006494,stroke:#888,color:#e0e0e0
    style BMAL1 fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style EGLN2 fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style NLRP3_inhibition fill:#ef5350,stroke:#ff8a65,color:#e0e0e0
    style FOXO3 fill:#4a1a6b,stroke:#ce93d8,color:#e0e0e0
    style APOPTOSIS fill:#1b5e20,stroke:#81c784,color:#e0e0e0
    style TNF fill:#1b5e20,stroke:#81c784,color:#e0e0e0

Overview

Hypoxia-inducible factor 1-alpha (HIF-1α) is the oxygen-regulated subunit of the HIF-1 transcription factor complex. Under hypoxic conditions, HIF-1α escapes proteasomal degradation and translocates to the nucleus, where it dimerizes with constitutively expressed HIF-1β (ARNT) to activate genes involved in adaptation to low oxygen^{1https://doi.org/10.1073/pnas.92.12.55101995 · DOI 10.1073/pnas.92.12.5510](https://doi.org/10.1073/pnas.92.12.5510Open reference}.

In neurodegenerative diseases, HIF-1α plays complex roles: while its activation can be neuroprotective by promoting glycolysis, angiogenesis, and erythropoiesis, chronic or dysregulated HIF-1α signaling may contribute to neuroinflammation and neuronal dysfunction^{2https://doi.org/10.1177/10738584166690882017 · DOI 10.1177/1073858416669088](https://doi.org/10.1177/1073858416669088Open reference}.

Structure and Domains

HIF-1α contains:

• bHLH domain (1-80): Basic helix-loop-helix DNA binding

• PAS-A domain (90-199): Dimerization with HIF-1β

• PAS-B domain (201-329): Additional dimerization interface

• ODD domain (401-603): Oxygen-dependent degradation domain

  • Pro402, Pro564: Prolyl hydroxylation targets

  • Asn803: Asparaginyl hydroxylation site

• TAD-N (531-575): N-terminal transactivation domain

• TAD-C (786-826): C-terminal transactivation domain

Oxygen sensing mechanism: Under normoxia, prolyl hydroxylases (PHDs) hydroxylate Pro402 and Pro564, enabling von Hippel-Lindau (pVHL) E3 ligase binding and proteasomal degradation^{3https://doi.org/10.1126/science.10597962001 · DOI 10.1126/science.1059796](https://doi.org/10.1126/science.1059796Open reference}.

Normal Function

Hypoxia Response

When oxygen is limited:

1. PHD inactivation: Reduced prolyl hydroxylation

2. HIF-1α stabilization: Half-life increases from <5 min to >60 min

3. Nuclear translocation: HIF-1α enters nucleus

4. Dimerization: Forms HIF-1α/HIF-1β heterodimer

5. DNA binding: Binds hypoxia response elements (HREs)

6. Transcription: Activates target genes

Target Genes

HIF-1α regulates >200 genes involved in:

Physiological Roles

• Development: Embryonic survival requires HIF-1α

• Ischemia adaptation: Limits tissue damage during stroke

• Wound healing: Promotes revascularization

• Exercise: Muscle adaptation to training

Role in Neurodegeneration

Alzheimer’s Disease

HIF-1α shows complex alterations in AD^{4https://doi.org/10.1007/s00018-009-0108-12009 · DOI 10.1007/s00018-009-0108-1](https://doi.org/10.1007/s00018-009-0108-1Open reference}:

• Reduced HIF-1α: Lower levels in AD hippocampus and cortex

• Impaired hypoxia response: Blunted transcriptional activation

• Aβ effects: Acute Aβ induces HIF-1α; chronic exposure suppresses it

• Tau pathology: Tau may interfere with HIF-1α nuclear translocation

• Cerebral hypoperfusion: Vascular dysfunction creates chronic low-grade hypoxia

Evidence: Reduced HIF-1α target gene expression correlates with cognitive decline in AD patients^{5https://doi.org/10.1016/j.arr.2023.1020102023 · DOI 10.1016/j.arr.2023.102010](https://doi.org/10.1016/j.arr.2023.102010Open reference}.

Parkinson’s Disease

• Dopaminergic vulnerability: Substantia nigra has high oxygen demand

• HIF-1α neuroprotection: Stabilization protects dopaminergic neurons

• Iron dysregulation: Altered HIF-1α affects iron homeostasis

• DJ-1 interaction: DJ-1 (PARK7) stabilizes HIF-1α under oxidative stress

Therapeutic angle: Erythropoietin (EPO) and HIF prolyl hydroxylase inhibitors show promise in PD models^{6https://doi.org/10.1016/j.expneurol.2020.1132742020 · DOI 10.1016/j.expneurol.2020.113274](https://doi.org/10.1016/j.expneurol.2020.113274Open reference}.

Stroke and Ischemia

• Acute activation: HIF-1α rapidly induced after ischemic stroke

• Dual roles: Protective (glycolysis, angiogenesis) and damaging (inflammation, BBB breakdown)

• Timing matters: Early activation protective; delayed may be harmful

• Preconditioning: Brief hypoxia activates HIF-1α and induces tolerance

Huntington’s Disease

• Mitochondrial dysfunction: Impaired oxidative phosphorylation

• **HIF-1α dysregulation: Reduced nuclear HIF-1α in HD models

• PDK1: HIF-1α target that inhibits pyruvate dehydrogenase

• Metabolic shift: HD neurons show impaired glycolytic adaptation

ALS

• Motor neuron hypoxia: High metabolic demand, vulnerable to ischemia

• HIF-1α targets: EPO, VEGF show neuroprotective effects

• TDP-43 interaction: May affect HIF-1α regulation

• SOD1: Mutant SOD1 may alter HIF-1α stability

Therapeutic Targeting

HIF Prolyl Hydroxylase Inhibitors (HIF-PHIs)

Drugs that inhibit PHDs, stabilizing HIF-1α^{7https://doi.org/10.1016/j.kint.2017.06.0142017 · DOI 10.1016/j.kint.2017.06.014](https://doi.org/10.1016/j.kint.2017.06.014Open reference}:

• Roxadustat (FG-4592): FDA-approved for anemia in CKD

• Daprodustat (GSK1278863): Also approved for anemia

• Vadadustat (AKB-6548): In clinical development

• Molidustat (BAY 85-3934): Approved in Japan

Neurodegeneration potential: HIF-PHIs may protect neurons by activating hypoxia adaptation pathways without actual hypoxia.

Erythropoietin (EPO)

HIF-1α target with neuroprotective properties^{8https://doi.org/10.1002/14651858.CD004753.pub62023 · DOI 10.1002/14651858.CD004753.pub6](https://doi.org/10.1002/14651858.CD004753.pub6Open reference}:

• Mechanisms: Anti-apoptotic, anti-inflammatory, angiogenic

• BBB penetration: Limited, but intranasal delivery possible

• Clinical trials: Mixed results in stroke; ongoing in MS

DMOG and Other PHD Inhibitors

• DMOG: Research tool, stabilizes HIF-1α

• FG-4497: Neuroprotective in stroke models

• CoCl2: Classical hypoxia mimetic (toxicity limits use)

Natural HIF Activators

• Resveratrol: May stabilize HIF-1α

• Curcumin: Complex effects on HIF pathway

• Exercise: Physiological HIF-1α activation

Key Interactions

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• UniProt: Q16665

• PDB structures